Study Evaluated Alternative Dosing for ERZOFRI
Researchers modeled new maintenance intervals for the schizophrenia drug using pharmacokinetic simulations.
Updated on Sept. 23, 2026 in Alzheimer’s
Live Poll
Do you believe alternative dosing research effectively improves long-term medication adherence for psychiatric patients?
A study published in The Journal of Clinical Psychiatry suggests that 351 mg doses of ERZOFRI could potentially match the steady-state exposure of currently approved regimens. The modeling proposes maintenance intervals of four or six weeks, although no clinical data currently support these alternatives.
Why it matters
Improving flexible dosing intervals is a key strategy for addressing the persistent challenge of medication adherence in schizophrenia care. These findings offer a potential framework for future studies on optimizing treatment regimens for patients.
Pharmacokinetic modeling indicates that 351 mg every four weeks or every six weeks provides steady-state exposure comparable to 234 mg every three or four weeks, respectively. Current FDA-approved maintenance dosing for ERZOFRI is limited to 234 mg monthly.
The players
The Journal of Clinical Psychiatry
This is a peer-reviewed academic journal that publishes research on the diagnosis and treatment of psychiatric disorders.
Luye Pharma Group
This is the pharmaceutical company that developed ERZOFRI and maintains an operational presence in Princeton, New Jersey.
The details
Researchers utilized data from two Phase 1 clinical studies to perform simulations aimed at investigating steady-state paliperidone exposure. While the modeling suggests comparable exposure at higher doses and extended intervals, these findings remain theoretical and have not yet been validated in clinical settings.
Timeline
ERZOFRI received U.S. Food and Drug Administration approval in 2024.
The drug became available for use in the United States in April 2025.
The study appeared in The Journal of Clinical Psychiatry in September 2026.
Health Landscape
This research follows a pattern of using pharmacokinetic modeling to explore off-label dosage optimizations within the mental health field. The study departs from the established dosage schedule found in the FDA-approved prescribing information for ERZOFRI to test potential adherence improvements.
Patients currently prescribed ERZOFRI should continue to follow their healthcare provider's instructions based on existing FDA-approved guidelines. The alternative dosing regimens discussed in the study are not yet cleared for clinical use and carry unknown risks.
The takeaway
While pharmacokinetic modeling provides an interesting theoretical look at future treatment possibilities, it cannot substitute for clinical safety data. Patients and caregivers should prioritize adherence to currently approved medication schedules to ensure clinical efficacy.
Further reading
For broader context on current challenges in mental health treatment, visit the Alzheimer’s section.
More information
Read the complete ERZOFRI full prescribing information on the manufacturer's website.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you believe alternative dosing research effectively improves long-term medication adherence for psychiatric patients?
